Treatment with the Kv7 potassium channel activator flupirtine is beneficial in two independent mouse models of pulmonary hypertension

British Journal of Pharmacology

Volumn 157, Issue 7, 2009, Pages 1241-1249

  Morecroft, Ian ^a   Murray, A ^a   Nilsen, M ^a   Gurney, A M ^b   MacLean, M R ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

5 HT; Kv7 channels; Pulmonary hypertension

Indexed keywords

FLUPIRTINE; LINOPIRDINE; VOLTAGE GATED POTASSIUM CHANNEL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY CONSTRICTION; ARTERY DILATATION; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; ELECTROMYOGRAPHY; FEMALE; HEART RIGHT VENTRICLE HYPERTROPHY; HEART RIGHT VENTRICLE PRESSURE; HYPOXIA; LUNG BLOOD VESSEL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PULMONARY ARTERY; PULMONARY HYPERTENSION;

AMINOPYRIDINES; ANIMALS; ANOXIA; DISEASE MODELS, ANIMAL; FEMALE; HYPERTENSION, PULMONARY; MICE; MUSCLE CONTRACTION; MUSCLE RELAXATION; MUSCLE, SMOOTH, VASCULAR; POTASSIUM CHANNELS, VOLTAGE-GATED; PULMONARY ARTERY; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS;

EID: 70350344951     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2009.00283.x     Document Type: Article

References (67)

1. Alexander SP, Mathie A, Peters JA (2008). Guide to Receptors and Channels (GRAC), 3rd edition. Br J Pharmacol 153 (Suppl. 2): S1-S209.
2. Archer SL, Souil E, Dinh-Xuan AT, Schremmer B, Mercier JC, El Yaa-goubi A et al. (1998). Molecular identification of the role of voltage-gated K+ channels, Kv1.5 and Kv2.1, in hypoxic pulmonary vasoconstriction and control of resting membrane potential in rat pulmonary artery myocytes. J Clin Invest 101: 2319-2330
3. Bentzen BH, Schmitt N, Calloe K, Dalby BW, Grunnet M, Olesen SP (2006). The acrylamide (S)-1 differentially affects Kv7 (KCNQ) potassium channels. Neuropharmacology 51: 1068-1077
4. Burg ED, Remillard CV, Yuan JXJ (2008). Potassium channels in the regulation of pulmonary artery smooth muscle cell proliferation and apoptosis: pharmacotherapeutic implications. British Journal of Pharmacology 153: S99-S111
5. Calloe K, Nielsen MS, Grunnet M, Schmitt N, Jorgensen NK (2007). KCNQ channels are involved in the regulatory volume decrease response in primary neonatal rat cardiomyocytes. Biochimica et Biophysica Acta-Molecular. Cell Research 1773: 764-773
6. Chin KM, Rubin LJ (2008). Pulmonary arterial hypertension. J Am Coll Cardiol 51: 1527-1538
7. Clapp LH, Gurney AM (1992). ATP-sensitive K+ channels regulate resting potential of pulmonary arterial smooth muscle cells. Am J Physiol 262: H916-H920
8. Coetzee WA, Amarillo Y, Chiu J, Chow A, Lau D, McCormack T et al. (1999). Molecular diversity of K+ channels. Ann N Y Acad Sci 868: 233-285
9. Cogolludo A, Moreno L, Lodi F, Frazziano G, Cobeno L, Tamargo J et al. (2006). Serotonin inhibits voltage-gated K+ currents in pulmonary artery smooth muscle cells: role of 5-HT2A receptors, caveolin-1, and KV1.5 channel internalization 1. Circ Res 98: C931-C938
10. Daly CJ, Deighan C, Mcgee A, Mennie D, Ali Z, McBride M et al. (2002). A knockout approach indicates a minor vasoconstrictor role for vascular alpha(1B)-adrenoceptors in mouse. Physiol Genomics 9: 85-91
11. Evans AM, Osipenko ON, Gurney AM (1996). Properties of a novel K+ current that is active at resting potential in rabbit pulmonary artery smooth muscle cells. J Physiol (London) 496: 407-420
12. Friedel HA, Fitton A (1993). Flupirtine-a review of its pharmacological properties, and therapeutic efficacy in pain states. Drugs 45: 548-569
13. Galie N, Ghofrani HA, Torbicki A, Barst RJ, Rubin LJ, Badesch D et al. (2005). Sildenafil citrate therapy for pulmonary arterial hypertension. New England. J Med 353: 2148-2157
14. Galie N, Olschewski H, Oudiz RJ, Torres F, Frost A, Ghofrani HA et al. (2008). Ambrisentan for the treatment of pulmonary arterial hypertension-results of the Ambrisentan in Pulmonary Arterial Hypertension, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Efficacy (ARIES) Study 1 and 2. Circulation 117: 3010-3019
15. Gardener MJ, Johnson IT, Burnham MP, Edwards G, Heagerty AM, Weston AH (2004). Functional evidence of a role for two-pore domain potassium channels in rat mesenteric and pulmonary arteries. Br J Pharmacol 142: 192-202
16. Greenwood IA, Yeung SY, Hettiarachi S, Andersson M, Baines DL (2009). KCNQ-encoded channels regulate Na(+) transport across H441 lung epithelial cells. Pflugers Arch 457: 785-794
17. Grissmer S, Nguyen AN, Aiyar J, Hanson DC, Mather RJ, Gutman GA et al. (1994). Pharmacological characterization of five cloned voltage-gated K+ channels, types Kv1.1, 1.2, 1.3, 1.5, and 3.1, stably expressed in mammalian cell lines. Mol Pharmacol 45: 1227-1234
18. Guignabert C, Izikki M, Tu LI, Li ZL, Zadigue P, Barlier-Mur AM et al. (2006). Transgenic mice overexpressing the 5-hydroxytryptamine transporter gene in smooth muscle develop pulmonary hypertension. Circ Res 98: 1323-1330
19. Gurney AM, Osipenko ON, MacMillan D, McFarlane KM, Tate RJ, Kempsill FEJ (2003). Two-pore domain K channel, TASK-1, in pulmonary artery smooth muscle cells. Circulation Research 93: 957-964
20. Hadley JK, Noda M, Selyanko AA, Wood IC, Abogadie FC, Brown DA (2000). Differential tetraethylammonium sensitivity of KCNQ1-4 potassium channels. Br J Pharmacol 129: 413-415
21. Herrmann WM, Kern U, Aigner M (1987). On the adverse reactions and efficacy of long-term treatment with flupirtine-preliminary results of an ongoing 12-month study with 200 patients suffering from chronic pain states in arthrosis or arthritis. Postgrad Med J 63: 87-103
22. Humbert M, Morrell NW, Archer SL, Stenmark KR, MacLean MR, Lang IM et al. (2004). Cellular and molecular pathobiology of pulmonary arterial hypertension 11. J Am Coll Cardiol 43: 13S-24S (Pubitemid 38759713)
23. Hummel T, Friedmann T, Pauli E, Niebch G, Borbe HO, Kobal G (1991). Dose-related analgesic effects of flupirtine. Br J Clin Pharmacol 32: 69-76
24. Jensen HS, Callo K, Jespersen T, Jensen BS, Olesen SP (2005). The KCNQ5 potassium channel from mouse: a broadly expressed M-current like potassium channel modulated by zinc, pH, and volume changes. Brain Res Mol Brain Res 139: 52-62
25. Jentsch TJ (2000). Neuronal KCNQ potassium channels: physiology and role in disease. Nat Rev Neurosci 1: 21-30
26. Jespersen T, Grunnet M, Olesen SP (2005). The KCNQ1 potassium channel: from gene to physiological function. Physiology (Bethesda) 20: 408-416
27. Jin Z, Liang GH, Cooper EC, Jarlebark L (2008). Expression and Localization of K Channels KCNQ2 and KCNQ3 in the Mammalian Cochlea. Audiol Neurootol 14: 98-105
28. Joshi S, Balan P, Gurney AM (2006). Pulmonary vasoconstrictor action of KCNQ potassium channel blockers. Respir Res 7: 31
29. Joshi S, Sedivy V, Hodyc D, Herget J, Gurney A (2008). A role for KCNQ channels in hypoxia-induced pulmonary vasoconstriction and hypertension. Fund Clin Pharmacol 22: 27
30. Joshi S, Sedivy V, Hodyc D, Herget J, Gurney AM (2009). KCNQ modulators reveal a key role for KCNQ potassium channels in regulating the tone of rat pulmonary artery smooth muscle. J Pharmacol Exp Ther 329: 368-376
31. Keegan A, Morecroft I, Smillie D, Hicks MN, MacLean MR (2001). Contribution of the 5-HT1B receptor to hypoxia-induced pulmonary hypertension-converging evidence using 5-HT1B-receptor knockout mice and the 5-HT1B/1D-receptor antagonist GR127935. Circ Res 89: 1231-1239
32. Lamas JA, Selyanko AA, Brown DA (1997). Effects of a cognition-enhancer, linopirdine (DuP 996), on M-type potassium currents (IK(M)) and some other voltage-and ligand-gated membrane currents in rat sympathetic neurons. Eur J Neurosci 9: 605-616
33. Lane KB, Machado RD, Pauciulo MW, Thomson JR, Phillips JA, III, Loyd JE et al. (2000). Heterozygous germline mutations in BMPR2, encoding a TGF-beta receptor, cause familial primary pulmonary hypertension. The International PPH Consortium. Nat Genet 26: 81-84
34. McCallum LA, Greenwood IA, Tribe RM (2009). Expression and function of K(v)7 channels in murine myometrium throughout oestrous cycle. Pflugers Arch 457: 1111-1120
35. Machado RD, Pauciulo MW, Thomson JR, Lane KB, Morgan NV, Wheeler L et al. (2001). BMPR2 haploinsufficiency as the inherited molecular mechanism for primary pulmonary hypertension. Am J Hum Genet 68: 92-102
36. Mackie AR, Brueggemann LI, Henderson KK, Shiels AJ, Cribbs LL, Scrogin KE et al. (2008). Vascular KCNQ potassium channels as novel targets for the control of mesenteric artery constriction by vasopressin, based on studies in single cells, pressurized arteries, and in vivo measurements of mesenteric vascular resistance. J Pharmacol Exp Ther 325: 475-483
37. MacLean MR, Deuchar GA, Hicks MN, Morecroft I, Shen SB, Sheward J et al. (2004). Overexpression of the 5-hydroxytryptamine transporter gene-effect on pulmonary hemodynamics and hypoxia-induced pulmonary hypertension. Circulation 109: 2150-2155
38. Main MJ, Cryan JE, Dupere JRB, Cox B, Clare JJ, Burbidge SA (2000). Modulation of KCNQ2/3 potassium channels by the novel anticon-vulsant retigabine. Mol Pharmacol 58: 253-262
39. Mair KM, MacLean MR, Morecroft I, Dempsie Y, Palmer TM (2008). Novel interactions between the 5-HT transporter, 5-HT(1B) receptors and Rho kinase in vivo and in pulmonary fibroblasts. Br J Pharmacol 155: 606-616
40. Marrion NV (1997). Control of M-current. Annu Rev Physiol 59: 483-504
41. Morecroft I, Dempsie Y, Bader M, Walther DJ, Kotnik K, Loughlin L et al. (2007). Effect of tryptophan hydroxylase 1 deficiency on the development of hypoxia-induced pulmonary hypertension. Hypertension 49: 232-236
42. Nickel B (1987). The antinociceptive activity of flupirtine: a structurally new analgesic. Postgrad Med J 63 (Suppl. 3): 19-28
43. Ohya S, Sergeant GP, Greenwood IA, Horowitz B (2003). Molecular variants of KCNQ channels expressed in murine portal vein myo-cytes: a role in delayed rectifier current. Circ Res 92: 1016-1023
44. Olschewski A, Li Y, Tang B, Hanze J, Eul B, Bohle RM et al. (2006). Impact of TASK-1 in Human Pulmonary Artery Smooth Muscle Cells. Circ Res 98: 1072-1080
45. Osipenko ON, Alexander D, MacLean MR, Gurney AM (1988). Influence of chronic hypoxia on the contributions of non-inactivating and delayed rectifier K currents to the resting potential and tone of rat pulmonary artery smooth muscle. Br J Pharmacol 124: 1335-1337
46. Platoshyn O, Golovina VA, Bailey CL, Limsuwan A, Krick S, Juhaszova M et al. (2000). Sustained membrane depolarization and pulmonary artery smooth muscle cell proliferation. Am J Physiol 279: C1540-C1549
47. Platoshyn O, Yu Y, Golovina VA, McDaniel SS, Krick S, Li L et al. (2001). Chronic hypoxia decreases K-V channel expression and function in pulmonary artery myocytes. Am J Physiol 280: L801-L812
48. Remillard CV, Tigno DD, Platoshyn O, Burg ED, Brevnova EE, Conger D et al. (2007). Function of Kv1.5 channels and genetic variations of KCNA5 in patients with idiopathic pulmonary arterial hypertension. Am J Physiol 292: C1837-C1853
49. Robbins J (2001). KCNQ potassium channels: physiology, pathophysi-ology, and pharmacology. Pharmacol Ther 90: 1-19
50. Rubin LJ, Badesch DB, Barst RJ, Galie N, Black CM, Keogh A et al. (2002). Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 346: 896-903 (Pubitemid 34984638)
51. Sanguinetti MC, Curran ME, Zou A, Shen J, Spector PS, Atkinson DL et al. (1996). Coassembly of K(v)LQT1 and minK (IsK) proteins to form cardiac I-Ks potassium channel. Nature 384: 80-83
52. Schenzer A, Friedrich T, Pusch M, Saftig P, Jentsch TJ, Grotzinger J et al. (2005). Molecular determinants of KCNQ (K(V)7) K+ channel sensitivity to the anticonvulsant retigabine. J Neurosci 25: 5051-5060
53. Schmidt WJ, Schuster G, Wacker E, Pergande G (1997). Antiparkinso-nian and other motor effects of flupirtine alone and in combination with dopaminergic drugs. Eur J Pharmacol 327: 1-9
54. Schnee ME, Brown BS (1998). Selectivity of linopirdine (DuP 996), a neurotransmitter release enhancer, in blocking voltage-dependent and calcium-activated potassium currents in hippocampal neurons. J Pharmacol Exp Ther 286: 709-717
55. Simonneau G, Galie N, Rubin LJ, Langleben D, Seeger W, Domenighetti G et al. (2004). Clinical classification of pulmonary hypertension. J Am Coll Cardiol 43: 5S-12S
56. Smirnov SV, Robertson TP, Ward JPT, Aaronson PI (1994). Chronic hypoxia is associated with reduced delayed rectifier K+ current in rat pulmonary-artery muscle-cells. Am J Physiol 266: H365-H370
57. Sun HS, Hui K, Lee DW, Feng ZP (2007). Zn2+ sensitivity of high-and low-voltage activated calcium channels. Biophys J 93: 1175-1183
58. Szelenyi I, Nickel B, Borbe HO, Brune K (1989). Mode of antinocice-ptive action of flupirtine in the rat. Br J Pharmacol 97: 835-842
59. Tatulian L, Delmas P, Abogadie FC, Brown DA (2001). Activation of expressed KCNQ potassium currents and native neuronal M-type potassium currents by the anti-convulsant drug retigabine. J Neuro-sci 21: 5535-5545
60. Wladyka CL, Kunze DL (2006). KCNQ/M-currents contribute to the resting membrane potential in rat visceral sensory neurons. J Physiol 575: 175-189
61. Wuttke TV, Seebohm G, Bail S, Maljevic S, Lerche H (2005). The new anticonvulsant retigabine favors voltage-dependent opening of the K(v)7.2 (KCNQ2) channel by binding to its activation gate. Mol Pharmacol 67: 1009-1017
62. Yeung S, Schwake M, Pucovsky V, Greenwood I (2008). Bimodal effects of the Kv7 channel activator retigabine on vascular K+ currents. Br J Pharmacol 155: 62-72
63. Yeung SY, Pucovsky V, Moffatt JD, Saldanha L, Schwake M, Ohya S et al. (2007). Molecular expression and pharmacological identification of a role for K(v)7 channels in murine vascular reactivity. Br J Pharmacol 151: 758-770
64. Yoro SG, Urosevic D, Fellmann L, Greney H, Bousquet P, Feldman J (2008). G-protein inwardly rectifying potassium channels are involved in the hypotensive effect of I1-imidazoline receptor selective ligands. J Hypertens 26: 1025-1032
65. Young KA, Ivester C, West J, Carr M, Rodman DM (2006). BMP signaling controls PASMC KV channel expression in vitro and in vivo. Am J Physiol Lung Cell Mol Physiol 290: L841-L848
66. Yuan JXJ, Aldinger AM, Juhaszova M, Wang J, Conte JV, Gaine SP et al. (1998). Dysfunctional voltage-gated K+ channels in pulmonary artery smooth muscle cells of patients with primary pulmonary hypertension. Circulation 98: 1400-1406 (Pubitemid 28462800)
67. Zhao L, Mason NA, Morrell NW, Kojonazarov B, Sadykov A, Maripov A et al. (2001). Sildenafil inhibits hypoxia-induced pulmonary hypertension. Circulation 104: 424-428